BJDX.NASDAQBluejay Diagnostics, INC

S-1/A: Bluejay Diagnostics Announces Proposed Public Offering to Fund FDA Approval Efforts and Repay Debt

Sentiment:

S-1/A Filing (Amendment No. 1)

📋All filings for Bluejay Diagnostics, INC
🔒Login to Follow

Bluejay Diagnostics is offering 2,906,977 units, each consisting of one share of common stock (or a prefunded warrant), two Class C warrants, and one Class D warrant, to raise capital for FDA approval activities and debt repayment.

Delay expectedThe company has slowed the timeline of its clinical trial work to preserve cash resources in the near-term.The company expects that this will delay its Symphony platform regulatory submission timeline until 2025.
Capital raiseBluejay Diagnostics is undertaking a public offering of 2,906,977 units, each comprising one share of common stock (or a prefunded warrant), two Class C warrants, and one Class D warrant.The company intends to use the net proceeds to repay $2.3 million in outstanding debt and fund FDA approval efforts, research and development, and general working capital.The company has recently obtained $2 million in bridge financing that will need to be repaid from the proceeds of this offering.
Worse than expectedThe company has a history of significant losses and a going concern uncertainty.The company is dependent on raising additional capital to continue operations.The company faces potential Nasdaq delisting due to non-compliance with minimum bid price requirements.

Summary

  • Bluejay Diagnostics is undertaking a public offering of 2,906,977 units, each comprising one share of common stock (or a prefunded warrant), two Class C warrants, and one Class D warrant.
  • The assumed public offering price is $3.01 per unit, based on the last reported sale price of the common stock on June 21, 2024.
  • The company intends to use the net proceeds to repay $2.3 million in outstanding debt and fund FDA approval efforts, research and development, and general working capital.
  • The offering includes prefunded warrants for purchasers who would otherwise exceed beneficial ownership limits.
  • The Class C warrants are exercisable upon warrant stockholder approval at $3.01 per share and expire five years from approval.
  • The Class D warrants are exercisable immediately, with the exercise price and number of shares subject to adjustment.
  • Aegis Capital Corp. is the underwriter for the offering and has a 45-day option to purchase additional shares and/or warrants.
  • The company has a history of losses and faces a going concern uncertainty, requiring additional funding to continue operations.
  • Bluejay Diagnostics has received a Nasdaq notification regarding minimum bid price non-compliance and could face delisting.
  • The company has recently obtained $2 million in bridge financing that will need to be repaid from the proceeds of this offering.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a history of losses, a going concern uncertainty, and dependence on additional funding. While there are positive aspects, such as the potential for FDA approval and ongoing clinical trials, the overall sentiment is negative due to the company's financial instability and operational risks.

Positives

  • The offering aims to secure funding for FDA approval, potentially leading to commercialization of the Symphony platform.
  • The company has a licensing agreement with Toray for its cartridge technology.
  • The company has contracts with Toray and Sanyoseiko for manufacturing.
  • The company is focusing on the SYMON-II pivotal clinical study in Q3 2024, which could support a 510(k) application to the FDA in 2025.
  • The company has identified IL-6 as a potential predictor of mortality in sepsis patients.

Negatives

  • The company has a history of significant losses and a going concern uncertainty.
  • The company is dependent on raising additional capital to continue operations.
  • The company faces potential Nasdaq delisting due to non-compliance with minimum bid price requirements.
  • The company has a limited number of full-time employees.
  • The company has a significant number of warrants outstanding, which could dilute existing shareholders.
  • The company has recently obtained $2 million in bridge financing that will need to be repaid from the proceeds of this offering.

Risks

  • The company may not be able to obtain additional funding on acceptable terms or at all.
  • The company's clinical trials and FDA submission timeline could be delayed.
  • The company could be forced to cease operations and liquidate assets.
  • The company's common stock price may be volatile.
  • The company may face delisting from Nasdaq.
  • The company is dependent on third-party manufacturers.
  • The company may face product liability suits.
  • The company may face raw material shortages and supplier disruptions.
  • The company's success depends on obtaining FDA approval for its Symphony products.
  • The company's ability to raise additional capital via a registered public offering on Form S-3 will be limited in the near-term as a result of the SECs baby shelf rules.

Future Outlook

The company expects negative cash flow to continue over at least the next 12 months as it conducts clinical trials and prepares for a potential FDA submission. The company aims to initiate the SYMON-II pivotal clinical study in the third quarter of 2024 and submit a 510(k) application to the FDA in 2025, contingent upon raising additional capital.

Industry Context

Bluejay Diagnostics is operating in the in vitro diagnostics (IVDs) market, targeting critical care facilities with rapid tests for infectious, inflammatory, and metabolic diseases. The company aims to compete with larger laboratory equipment providers by offering a mobile, rapid testing platform.

Comparison to Industry Standards

  • Bluejay's primary competition in the IL-6 market includes laboratory size equipment such as Roche Cobas, Siemens ADVIA Centaur, and Beckman Coulter Access 2.
  • These competitors require pre-processing of whole blood, while Bluejay's technology uses whole blood directly, potentially offering a competitive advantage.
  • The document does not provide specific comparisons to industry benchmarks in terms of financial performance or market share.
  • The document does not provide specific comparisons to industry benchmarks in terms of product performance or regulatory timelines.

Stakeholder Impact

  • Shareholders face potential dilution from the offering and outstanding warrants.
  • Shareholders face the risk of losing their investment if the company is unable to continue as a going concern.
  • Employees face uncertainty due to the company's financial instability.
  • Customers may experience delays in product availability due to the company's financial constraints.
  • Creditors face the risk of non-payment if the company is unable to raise sufficient capital.

Next Steps

  • The company intends to initiate the SYMON-II pivotal clinical study in the third quarter of 2024.
  • The company intends to use SYMON-II as support in a 510(k) application to the FDA in 2025.
  • The company intends to seek warrant stockholder approval.
  • The company intends to take all reasonable measures available to achieve compliance to allow for continued listing on the Nasdaq Capital Market.

Key Dates

DateDescription
March 20, 2015Bluejay Diagnostics, Inc. was incorporated in Delaware.
October 6, 2020Bluejay entered into a License and Supply Agreement with Toray.
November 2021Bluejay's initial public offering.
July 21, 2023Filed a Certificate of Amendment to effect a 1-for-20 reverse stock split.
July 24, 20231-for-20 reverse stock split became effective.
August 24, 2023Entered into a securities purchase agreement for a registered direct offering and concurrent private placement.
August 28, 2023Registered direct offering and concurrent private placement closed.
October 23, 2023Entered into an Amended and Restated License Agreement and a Master Supply Agreement with Toray.
December 27, 2023Commenced a public offering for the issuance and sale of common stock and prefunded warrants.
January 2, 2024Public offering closed.
February 28, 2024Received Nasdaq notification of non-compliance with minimum bid price rule.
First Quarter 2024Initiated multicenter Symphony IL-6 MONitoring Sepsis (SYMON) clinical studies.
June 17, 2024Filed a Certificate of Amendment to effect a 1-for-8 reverse stock split.
June 20, 20241-for-8 reverse stock split became effective.
June 21, 2024Last reported sale price of common stock on Nasdaq was $3.01 per share.
May 31, 2024Entered into a Note Purchase Agreement and a Securities Purchase Agreement.
June 3, 2024Transactions under the Note Purchase Agreement and Securities Purchase Agreement closed.
Third Quarter 2024Planning to initiate the SYMON-II pivotal clinical study.
August 26, 2024Deadline to regain compliance with Nasdaq minimum bid price requirement.
September 1, 2024Maturity date for notes issued under the NPA and SPA if the offering does not occur.
2025Intends to use SYMON-II as support in a 510(k) application to the FDA.
December 31, 2027Latest date Bluejay may remain an emerging growth company.

Keywords

Bluejay Diagnostics, public offering, FDA approval, Symphony platform, warrants, IL-6, clinical trials, debt repayment, financing, diagnostics

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.